REG - Uniphar PLC - AGM Results

UnipharAnnouncement

Thu 14:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250508:nRSH9370Ha&default-theme=true

RNS Number : 9370H  Uniphar PLC  08 May 2025

AGM Results

 

Dublin, London | 8 May 2025

 

Uniphar plc (the Company) is pleased to announce that at its Annual General
Meeting held at 11.00 a.m. today, 8 May 2025, each of the resolutions set out
in the Notice of Annual General Meeting circulated to shareholders and made
available on the Company's website, www.uniphar.ie (http://www.uniphar.ie/) ,
(http://www.uniphar.ie/) were duly passed without amendment.

Details of votes cast are set out below:

 

 

       RESOLUTION                                                   For          For %    Against     Against  Withheld

                                                                                                      %
 1     Financial Statements and Reports                             153,243,069  99.17%   1,278,544   0.83%    132,837
 2     Final Dividend of                                            154,654,450  100.00%  0           0.00%    0

       €3.4m
 3(a)  Re-elect Ger Rabbette                                        153,894,576  99.51%   759,874     0.49%    0
 3(b)  Re-elect Tim Dolphin                                         153,864,527  99.51%   761,647     0.49%    28,276
 3(c)  Re-elect Paul Hogan                                          154,120,862  99.65%   533,588     0.35%    0
 3(d)  Re-elect Sue Webb                                            153,923,147  99.55%   703,027     0.45%    28,276
 3(e)  Re-elect Jim Gaul                                            146,614,423  94.80%   8,040,027   5.20%    0
 3(f)  Re-elect Liz Hoctor                                          154,548,421  99.93%   106,029     0.07%    0
 3(g)  Re-elect Maurice Pratt                                       151,621,344  98.04%   3,032,306   1.96%    800
 3(h)  Re-elect Valerie Sick                                        154,335,546  99.79%   318,904     0.21%    0
 4     Remuneration of Auditors                                     111,340,592  92.64%   8,849,615   7.36%    34,464,243
 5     Authority to allot relevant securities                       129,854,034  83.96%   24,800,416  16.04%   0
 6     Disapplication of pre- emption rights in                     153,651,591  99.35%   1,002,859   0.65%    0

       specified circumstances
 7     Disapplication of pre- emption rights in additional          124,033,872  80.46%   30,127,960  19.54%   492,618

       circumstances
 8     Authorise market purchases of the Company's Ordinary Shares  154,058,953  100.00%  0           0.00%    595,497
 9     Re-issuance of Treasury Shares                               154,654,450  100.00%  0           0.00%    0

 

 

--- ENDS ---

Contact details

 Uniphar Group                                            Tel: +353 (0) 1 428 7777

 Allan Smylie, Head of Strategy and IR

 Davy (Joint Corporate Broker, Nominated Advisor and      Tel: +353 (0) 1 679 6363

 Euronext Growth Listing Sponsor)

 Daragh O'Reilly

 Niall Gilchrist

 Ivan Murphy

 RBC Capital Markets (Joint Corporate Broker)             Tel: +44 (0) 20 7653 4000

 Jamil Miah

 Rupert Walford

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)  Tel: +44 (0) 20 7710 7600

 Matt Blawat

 Ben Maddison

 Francis North

 Q4 PR                                                    Tel: +353 (0) 1 475 1444

 Iarla Mongey, Public Relations Advisor to Uniphar Group

 

 

About Uniphar plc

Headquartered in Dublin, Ireland, the Uniphar Group is an international
diversified healthcare services business servicing the requirements of more
than 200 multinational pharmaceutical and medical technology manufacturers
across three divisions - Uniphar Medtech, Uniphar Pharma and Uniphar Supply
Chain & Retail. The Group is active in Europe, North America, APAC and
MENA and delivers to 160+ countries.

 

Uniphar solves problems for healthcare. We sit in the middle between the
manufacturers and their stakeholders, and we help them both to overcome the
problems of a new, complicated healthcare environment. The Company's vision is
to improve patient access to pharmaco-medical products and treatments by
enhancing connectivity between manufacturers and healthcare professionals and
their patients. Uniphar represents a strong combination of scale, growth, and
profitability.

 

Uniphar Medtech

Uniphar Medtech is a leading pan-European medical device distributor and
solutions partner. The Group's strategy for Uniphar Medtech is to grow our
service offering across Europe and expand our addressable market by serving
new specialities and new manufacturers.

 

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the
lifecycle of a pharmaceutical product. We enable pharma and biotech companies
to bring innovative medicines to global markets and provide healthcare
professionals with access to medicines they cannot source through traditional
channels. Our strategy is to build a leading platform to provide the
specialist support and expertise needed to improve access to these medicines.

 

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in
Ireland with a growing symbol group offering of retail pharmacies. The Group's
strategy for Uniphar Supply Chain & Retail is to grow our wholesale market
share, our symbol group network and our own brand, in-licenced and consumer
products portfolio.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMPKFBKNBKDOPK